EP3412313A1 - Temperature sensitive hydrogel composition including nucleic acid and chitosan - Google Patents

Temperature sensitive hydrogel composition including nucleic acid and chitosan Download PDF

Info

Publication number
EP3412313A1
EP3412313A1 EP16889476.4A EP16889476A EP3412313A1 EP 3412313 A1 EP3412313 A1 EP 3412313A1 EP 16889476 A EP16889476 A EP 16889476A EP 3412313 A1 EP3412313 A1 EP 3412313A1
Authority
EP
European Patent Office
Prior art keywords
temperature
chitosan
nucleic acid
sensitive hydrogel
hydrogel composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16889476.4A
Other languages
German (de)
French (fr)
Other versions
EP3412313A4 (en
EP3412313B1 (en
Inventor
Ik Soo Kim
Han Gyu Kim
Cheol Am Hong
Su Yeon Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaresearch Products Co Ltd
Original Assignee
Pharmaresearch Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaresearch Products Co Ltd filed Critical Pharmaresearch Products Co Ltd
Publication of EP3412313A1 publication Critical patent/EP3412313A1/en
Publication of EP3412313A4 publication Critical patent/EP3412313A4/en
Application granted granted Critical
Publication of EP3412313B1 publication Critical patent/EP3412313B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/02Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075Macromolecular gels
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2377/00Characterised by the use of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Derivatives of such polymers
    • C08J2377/04Polyamides derived from alpha-amino carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2405/00Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
    • C08J2405/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Definitions

  • the present invention relates to a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan.
  • a hydrogel is a polymer structure having a three-dimensional network structure containing a water phase (Rohindra D.R. et al., 2004), and the hydrogel is formed by covalent binding or non-covalent binding between hydrophilic polymers (Hwang June-seok, et al., 2008).
  • the hydrogel composed of various hydrophilic polymers has a high moisture content, leading to excellent biocompatibility, and thus many studies have been made for the application thereof as a biomaterial.
  • Hydrogels sensitive to stimuli such as pH, temperature, electric field, magnetic field, light, and ultrasonic waves, may be especially used in drug delivery systems allowing the controlled release according to the absence or presence of stimuli (Hoffman A.S., 2002).
  • temperature-sensitive hydrogels are most widely studied in cell carriers and drug delivery systems for tissue regeneration.
  • the reason is that many polymers exhibit temperature transition characteristics. Therefore, when a hydrophilic group capable of dissolving or swelling general polymers in water is introduced, the corresponding polymers are dissolved or swollen in water and thus the solubility of the polymers in water increases as the temperature increases, but the polymers composed of a hydrophilic portion and a hydrophobic portion, such as methyl, ethyl, and propyl, have a lower critical solution temperature (LCST) at which the solubility in water decreases as the temperature increases, and thus the polymers are condensed to form a gel when the temperature increases (Ward M.A. et al., 2011).
  • LCST critical solution temperature
  • a polymer composed of hydrophilic and hydrophobic portions is dissolved in water to become a sol state since the hydrogen bonding strength between the hydrophilic group of the polymer and a water molecule is strong, but when the temperature is increased, the binding strength between the hydrophobic group portions of the polymer is stronger than the hydrogen bonding strength, and thus the hydrophobic group portion of the polymer agglomerates to cause phase transition into a gel state.
  • this polymer solution is in a sol state, such as a fluid, at a general temperature
  • the mixing with a drug is allowable through simple mixing
  • a heat having a temperature equal to or higher than the body temperature is applied to the polymer solution
  • the polymer solution forms a gel, allowing a sustained release of a drug.
  • a polymer needs to be released out of the human body through the metabolism of the human body after being used in the human body. Therefore, it is important that temperature-sensitive hydrogels for medical or human application exhibit biocompatibility and biodegradability.
  • the reaction concentrations of the compositions are higher in the temperature-sensitive hydrogels shown by hydrophobic-hydrophilic linkage.
  • a high reaction concentration cannot only influence the human body by the injection of hydrogels into the human body, but also influence the degradation rates in the human body. Therefore, the development of hydrogels capable of exhibiting temperature sensitivity even at low concentrations can help developing safer biocompatible substances.
  • the polymers constituting hydrogels include: natural polymers, such as chitosan (Berger J. et al., 2004), alginate (Augst A.D. et al., 2006), dextran, hyaluronic acid, gelatin, and collagen; and synthetic polymers, such as poly(vinylalcohol) (Bodugoz-Senturk H., et al., 2009), polyethyleneimine (Jin R.H. et al., 2005), and poly(ethylene glycol) (Mahoney M.J. et al., 2006).
  • natural polymers such as chitosan (Berger J. et al., 2004), alginate (Augst A.D. et al., 2006), dextran, hyaluronic acid, gelatin, and collagen
  • synthetic polymers such as poly(vinylalcohol) (Bodugoz-Senturk H., et al
  • Chitosan may be produced by deacetylation of chitin, which is a natural polysaccharide in a ā‡ -(1 ā‡ 4)-linked form of N-acetyl-D-glucosamine that can be obtained from cellular walls of crustaceans, such as crab, general shrimp, and lobster; mollusks such as cuttlefish; insects; and bacteria. Chitosan is easily dissolved in an inorganic acid aqueous solution, and thus is utilized in various fields, such as coagulants for wastewater treatment, heavy metal adsorbents, foods, and cosmetics.
  • chitin is a natural polysaccharide in a ā‡ -(1 ā‡ 4)-linked form of N-acetyl-D-glucosamine that can be obtained from cellular walls of crustaceans, such as crab, general shrimp, and lobster; mollusks such as cuttlefish; insects; and bacteria.
  • Chitosan is easily dissolved in an inorganic acid aqueous solution, and thus is utilized
  • chitosan is a polysaccharide obtained from natural materials, and it has been reported that chitosan has excellent biocompatibility and biodegradability, cell association, biological tissue culture, and biological activities, such as antibacterial, aromatic, non-toxic, and hemostatic properties (Park Jun-gyu et al., 2015).
  • nucleic acids which have been recognized as a genome to store and deliver genetic information, are distributed around the diseased tissue to promote cell growth and differentiation and angiogenesis and perform an inflammation inhibitory function. That is, nucleic acids are degraded into small fragments outside cells and bind to receptors on the cell surface to stimulate signals into the cells.
  • Hydrogels composed of DNA have very excellent biocompatibility, and thus are medically studied in various fields.
  • the production results of functional DNA hydrogels that respond to heat and enzymes to induce free degradation and re-association have been recently reported (Xing Y. et al., 2011). Therefore, side effects due to overdosing of drugs can be reduced by enabling a smart drug delivery method in which drugs are allowed to flow only in case of necessity.
  • DNA hydrogels are composed of biomaterial DNA, and thus are not harmful to the human body, so the DNA hydrogels can be used as artificial tissues for wounded sites with various shapes and can be variously applied as an effective drug carrier in a medical field.
  • nucleic acids are easily degraded by degradation enzymes existing in the human body, so that the in vivo residence of nucleic acids for application of the nucleic acids to target disease tissues is low, resulting in a lack of drug persistence, and in the case where DNA hydrogels are utilized, the degradation of the nucleic acids by degradation enzymes causes a collapse of structures, and thus the DNA hydrogels may not properly perform as roles of artificial tissues and drug carriers (Lee Jong-beom, et al., 2012). Therefore, it is necessary to conduct research to enhance the drug persistence of nucleic acids and to solve the problems of DNA hydrogels.
  • the present inventors conducted continuous research in order to prepare a temperature-sensitive hydrogel, which exists in a sol state at room temperature and forms a gel when injected into the body, and as a result, the present inventors produced a temperature-sensitive hydrogel with biocompatibility and biodegradability through a combination of chitosan and a nucleic acid, and thus completed the present invention.
  • Korean Patent Publication No. 2014-0090670 as a prior art discloses an in-situ crosslinkable polymer composition, but never states temperature sensitivity and hydrogels.
  • the crosslinkable polymer composition of this patent publication contains about 0.1 wt% to about 95 wt% of more than one kind of polyanionic polymer, about 0.1 wt% to about 90 wt% of more than one kind of polycationic polymer, and 0.1 wt% to 99.8 wt% of water, and thus this polymer composition is different from a temperature-sensitive hydrogel composition of the present invention in view of the mixing ratio.
  • the patent publication discloses that the polyanions include crosslinkable and non-crosslinkable polyanions, and a polynucleotide is suggested as one of the non-crosslinkable polyanion components.
  • the patent publication discloses that the non-crosslinkable polyanions are further included in the polyanions, and it can be seen that the non-crosslinkable anions do not influence crosslinkage.
  • a temperature-sensitive hydrogel of the present invention is formed through a non-crosslinkage between a nucleic acid and chitosan, and thus it can be seen that the temperature-sensitive hydrogel of the present invention is different from the polymer composition in the patent publication in view of the constituent elements.
  • European Publication Patent No. 2745849 discloses a combination of polydeoxyribonucleotide (PDRN) and chitosan but does not state a temperature-sensitive hydrogel, wherein the combination contains 0.002-0.25 wt% of polydeoxyribonucleotide and 1-10 wt% of chitosan, which is different from the constitution of the present invention.
  • PDRN polydeoxyribonucleotide
  • chitosan which is different from the constitution of the present invention.
  • US Patent Publication No. 2015-0111834 discloses an in-situ gel composition, wherein an anti-gelation agent is introduced for prevention of gelation at room temperature, and thus it can be seen that the in-situ gel composition is different from the constitution of the present invention.
  • An aspect of the present invention is to provide a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan.
  • a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan, wherein the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1.
  • the present invention may be a temperature-sensitive hydrogel composition wherein the weight ratio of a nucleic acid and chitosan is preferably 50:1 to 2000:1 and most preferably 100:1 to 1000:1.
  • the content of the nucleic acid may be 0.01 wt% to 3 wt% relative to the total weight of the composition.
  • the nucleic acid may be deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof.
  • the content of the chitosan may be 1x10 -6 wt% to 0.15 wt% relative to the total weight of the composition.
  • the molecular weight of the chitosan may be 3 kDa to 1000 kDa.
  • the temperature-sensitive hydrogel composition may contain a polymer material as an additional ingredient.
  • the polymer material may be at least one selected from the group consisting of hyaluronic acid, poly-Y-glutamic acid, cellulose, polyacrylic acid, polyamino acids, alginate, and derivatives and a combination thereof.
  • a method for producing the temperature-sensitive hydrogel composition including: i) preparing a nucleic acid stock solution; ii) preparing a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of a nucleic acid and chitosan is 20:1 to 10000:1, followed by stirring; and iv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
  • the method may include: i) putting a nucleic acid in a buffer solution, and dissolving the nucleic acid in the buffer solution for 1-2 hours with stirring at 60-70Ā°C, to prepare a nucleic acid stock solution; ii) dissolving chitosan in an acidic buffer solution to prepare a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1, followed by stirring at 55-65Ā°C for 1-2 hours; and vi) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
  • the temperature-sensitive hydrogel composition may have an osmotic pressure of 100-500 mOsm and a pH value of 6-8.
  • the temperature-sensitive hydrogel refers to a hydrogel of which a phase transition occurs from a sol into a gel or a gel into a sol according to the temperature.
  • a transition of a sol into a gel is referred to as gelation.
  • the gelation in the present invention is defined by a state in which a polymer having viscoelasticity forms a three-dimensional network structure with increasing temperature, and thus remains without being dissolved in a solvent.
  • the sol-gel transition temperature thereof may vary according to the mixing ratio of a nucleic acid and chitosan, and here, the sol-gel transition temperature can be adjusted by changing the mixing ratio according to the purpose for use.
  • the temperature-sensitive hydrogel composition containing a nucleic acid and chitosan is highly stable in which a homogeneous state is maintained and the layer separation does not occur.
  • the weight ratio of the nucleic acid and the chitosan is in the range of preferably 20:1 to 10000:1, more preferably 50:1 to 2000:1, and most preferably 100:1 to 1000:1.
  • the content of the nucleic acid may be 0.01-3 wt%, preferably 0.1-2 wt%, and most preferably 1-1.5 wt% relative to the total weight of the composition.
  • the molecular weight of the nucleic acid may be 1-100,000 kDa, preferably 10-10,000 kDa, and most preferably 50-3,500 kDa.
  • the nucleic acid may be deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof.
  • the nucleic acid may be deoxyribonucleic acid.
  • the deoxyribonucleic acid may include oligonucleotides, polynucleotides, and polydeoxyribonucleotides (PDRN).
  • PDRN polydeoxyribonucleotides
  • the nucleic acid may form a hydrogel through a combination with chitosan, and can act as a therapeutic drug in the body.
  • the content of chitosan may be 1x10 -6 wt% to 0.15 wt%, preferably 1x10 -5 wt% to 0.1 wt%, and most preferably 1x10 -4 wt% to 0.075 wt%, relative to the total weight of the composition.
  • the molecular weight of chitosan is 3 kDa to 1000 kDa, but is not limited thereto.
  • the temperature-sensitive hydrogel composition may contain a polymer material as an additional ingredient, wherein the polymer material may be added to make secure the adjustment of physical property changes according to the use of the temperature-sensitive hydrogel containing the nucleic acid and chitosan.
  • the polymer material may employ at least one selected from the group consisting of hyaluronic acid, poly-Y-glutamic acid, cellulose, polyacrylic acid, polyamino acids, alginate, and derivatives and a combination thereof, but is not limited thereto.
  • the temperature-sensitive hydrogel composition may be used for a medical use and as a cosmetic agent.
  • a method for producing the temperature-sensitive hydrogel includes: i) putting a nucleic acid in a buffer solution, and dissolving the nucleic acid in the buffer solution for 1-2 hours with stirring at 60-70Ā°C, to prepare a nucleic acid stock solution; ii) dissolving chitosan in an acidic buffer solution to prepare a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1, followed by stirring at 55-65Ā°C for 1-2 hours; and iv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
  • the buffer solution that can be used in the preparation of the nucleic acid stock solution may employ sodium phosphate dibasic dodecahydrate, sodium chloride, magnesium chloride, potassium chloride, phosphate buffer saline, or HEPES (N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid) buffer solution, and preferably sodium phosphate dibasic dodecahydrate, but is not limited thereto.
  • the acidic buffer that can be used in the preparation of the chitosan stock solution may employ acetic acid, hydrochloric acid, ascorbic acid, lactic acid, and nitric acid, and preferably acetic acid, but is not limited thereto.
  • the mixing of the nucleic acid and the chitosan is conducted such that the weight ratio of nucleic acid and chitosan is 20:1 to 10000:1, and here, the content of the nucleic acid is 0.01-3 wt% relative to the total weight of the composition, and the content of the chitosan is 1x10 -6 wt% to 0.15 wt% relative to the total weight of the composition.
  • the osmotic pressure and pH thereof may be adjusted so that the composition can be injected into the human body or coated on the skin.
  • the production method may further include a step of adjusting pH in step iv).
  • the osmotic pressure of the temperature-sensitive hydrogel composition obtained by the production method may be 100-500 mOsm, preferably 150-450 mOsm, and most preferably 200-400 mOsm.
  • the pH of the temperature-sensitive hydrogel composition obtained by the production method may be 6-8, preferably 6.5-7.5, and most preferably 7.
  • the present invention provides a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan.
  • the hydrogel has excellent biocompatibility and biostability and exhibits a sol-gel transition property according to the temperature change, so that the hydrogel exists in a sol state at room temperature, and the hydrogel is gelated when the hydrogel has a high temperature by being injected into the body or coated on the epidermal skin surface.
  • the temperature-sensitive hydrogel of the present invention can be directly injected and coated on a particular site in needed of therapy, and can increase the time for drug persistence and drug attachment through the gelation according to the temperature, and thus the drug efficacy thereof can sufficiently exerted. Therefore, the temperature-sensitive hydrogel is expected to be utilized in various therapies.
  • nucleic acid and chitosan hydrogels were prepared with concentrations corresponding examples shown in table 1 below.
  • nucleic acid was put in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate, and then dissolved therein using a heat stirrer at 65Ā°C for 1 hour.
  • chitosan was dissolved using 100 mM acetic acid.
  • nucleic acid and chitosan stock solutions prepared with the concentrations in table 1 below were mixed at a weight ratio of 1:1, and stirred in a heat stirrer at 60Ā°C for 1 hour. Thereafter, the temperature was lowered to room temperature, followed by stirring for 1 hour, to produce nucleic acid-chitosan hydrogels.
  • a nucleic acid-chitosan-hyaluronic acid hydrogel was produced through the following procedure.
  • a nucleic acid was dissolved in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate to have a concentration of 2.2 wt%.
  • the nucleic acid were dissolved using a heat stirrer at 65Ā°C for 1 hour.
  • chitosan was dissolved in 100 mM acetic acid to have a concentration of 0.4 wt%.
  • Sodium hyaluronic acid was dissolved in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate to have a concentration of 2 wt%.
  • the sodium hyaluronic acid was dissolved using a heat stirrer at 40Ā°C for 30 minutes, followed by cooling to room temperature with stirring using a stirrer.
  • nucleic acid-chitosan-hyaluronic acid hydrogels of example 2 2.2 wt% of the prepared nucleic acid solution and 0.4 wt% of the prepared chitosan solution were mixed at a weight ratio of 9:1, followed by stirring in a heat stirrer at 65Ā°C for 10 minutes. 2 wt% of sodium hyaluronic acid was added to the nucleic acid-chitosan mixture solution at a weight ratio of 1:1, followed by stirring in a heat stirrer at 65Ā°C for 1 hour, and then the resulting solution was cooled to room temperature while the stirring maintained, thereby producing nucleic acid-chitosan-hyaluronic acid hydrogels of example 2.
  • Chitosan was dissolved using 100 mM acetic acid.
  • hydrogel compositions of example 1, example 2, comparative example 1, and comparative example 2 were used to investigate gelation, gel stability, and solubility thereof.
  • composition was subjected to mixing, and then the transparency and gelation state thereof were observed to the naked eye for 3 days.
  • the gelation was examined by viscoelasticity and the gel stability was examined by precipitate generation and layer separation.
  • the hydrogel composition of each of example 1, example 2, comparative example 1, and comparative example 2 was dropped in an aqueous solution at 37.5Ā°C, followed by gelation, and then the solubility of gel was examined while the stirring was conducted at 400 rpm for 5 minutes with the temperature maintained at 37.5Ā°C.
  • the results were shown in table 3 and FIGS. 1 and 2 .
  • the hydrogel composition of the present invention shows temperature sensitivity, high stability, and a gel form continuously maintained after gelation, and here, it was confirmed that the weight ratio of nucleic acid and chitosan plays a key role.
  • the temperature-sensitive hydrogel composition produced in each of example 1, example 2, comparative example 1, and comparative example 2 was examined for sol-gel transition.
  • a rheometer was used for the confirmation of sol-gel transition.
  • the measurement conditions used here were PU20, gap of 0.5 mm, 0.1 Hz, and 1% stress-strain, and the changes of G' (elasticity) and G" (viscosity) were measured while the temperature was raised from 24Ā°C to 40Ā°C by 1Ā°C and then was maintained for 1 minute.
  • G' elasticity
  • G" viscosity
  • the temperature-sensitive hydrogel of example 1-3 exhibited a gentle decrease width of G' (elasticity) and an increase of G" (viscosity) with an increasing temperature ( FIG. 3A ), which correspond to the feature of a temperature-sensitive hydrogel.
  • the temperature-sensitive hydrogel of example 1-3 exhibited a sol state at a temperature lower than 36Ā°C but was gelated at a temperature exceeding 36Ā°C ( FIG. 3B ). It was confirmed that these results were identical in all of the temperature-sensitive hydrogel compositions in examples 1 and 2. It can be seen from these results that the hydrogel compositions of the present invention show temperature sensitivity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a temperature sensitive hydrogel composition including a nucleic acid and chitosan. Since the hydrogel has excellent biocompatibility and biostability, and simultaneously has sol-gel phase transition properties depending on temperature changes, the hydrogel is present in a sol state at room temperature and becomes a gel when the hydrogel is injected into the human body or applied on the surface of epithelial skin and the temperature increases. Thus, the temperature-sensitive hydrogel of the present invention can be directly injected into and applied on certain parts requiring treatment and the retention and attaching time of a drug is increased through gelation depending on the temperature so that drug efficacy is sufficiently exhibited. Therefore, it is expected that the temperature-sensitive hydrogel of the present invention can be utilized for various treatments.

Description

    Technical Field
  • The present invention relates to a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan.
  • Background Art
  • A hydrogel is a polymer structure having a three-dimensional network structure containing a water phase (Rohindra D.R. et al., 2004), and the hydrogel is formed by covalent binding or non-covalent binding between hydrophilic polymers (Hwang June-seok, et al., 2008). The hydrogel composed of various hydrophilic polymers has a high moisture content, leading to excellent biocompatibility, and thus many studies have been made for the application thereof as a biomaterial. Hydrogels sensitive to stimuli, such as pH, temperature, electric field, magnetic field, light, and ultrasonic waves, may be especially used in drug delivery systems allowing the controlled release according to the absence or presence of stimuli (Hoffman A.S., 2002).
  • Of these, temperature-sensitive hydrogels are most widely studied in cell carriers and drug delivery systems for tissue regeneration. The reason is that many polymers exhibit temperature transition characteristics. Therefore, when a hydrophilic group capable of dissolving or swelling general polymers in water is introduced, the corresponding polymers are dissolved or swollen in water and thus the solubility of the polymers in water increases as the temperature increases, but the polymers composed of a hydrophilic portion and a hydrophobic portion, such as methyl, ethyl, and propyl, have a lower critical solution temperature (LCST) at which the solubility in water decreases as the temperature increases, and thus the polymers are condensed to form a gel when the temperature increases (Ward M.A. et al., 2011). That is, a polymer composed of hydrophilic and hydrophobic portions is dissolved in water to become a sol state since the hydrogen bonding strength between the hydrophilic group of the polymer and a water molecule is strong, but when the temperature is increased, the binding strength between the hydrophobic group portions of the polymer is stronger than the hydrogen bonding strength, and thus the hydrophobic group portion of the polymer agglomerates to cause phase transition into a gel state.
  • In the case where this polymer solution is in a sol state, such as a fluid, at a general temperature, the mixing with a drug is allowable through simple mixing, and in the case where a heat having a temperature equal to or higher than the body temperature is applied to the polymer solution, the polymer solution forms a gel, allowing a sustained release of a drug. However, such a polymer needs to be released out of the human body through the metabolism of the human body after being used in the human body. Therefore, it is important that temperature-sensitive hydrogels for medical or human application exhibit biocompatibility and biodegradability.
  • As for the content of the temperature-sensitive hydrogel composition, which has been studied until now, it can be seen that the reaction concentrations of the compositions are higher in the temperature-sensitive hydrogels shown by hydrophobic-hydrophilic linkage. A high reaction concentration cannot only influence the human body by the injection of hydrogels into the human body, but also influence the degradation rates in the human body. Therefore, the development of hydrogels capable of exhibiting temperature sensitivity even at low concentrations can help developing safer biocompatible substances.
  • The polymers constituting hydrogels include: natural polymers, such as chitosan (Berger J. et al., 2004), alginate (Augst A.D. et al., 2006), dextran, hyaluronic acid, gelatin, and collagen; and synthetic polymers, such as poly(vinylalcohol) (Bodugoz-Senturk H., et al., 2009), polyethyleneimine (Jin R.H. et al., 2005), and poly(ethylene glycol) (Mahoney M.J. et al., 2006).
  • Chitosan may be produced by deacetylation of chitin, which is a natural polysaccharide in a Ī²-(1ā†’4)-linked form of N-acetyl-D-glucosamine that can be obtained from cellular walls of crustaceans, such as crab, general shrimp, and lobster; mollusks such as cuttlefish; insects; and bacteria. Chitosan is easily dissolved in an inorganic acid aqueous solution, and thus is utilized in various fields, such as coagulants for wastewater treatment, heavy metal adsorbents, foods, and cosmetics. In addition, chitosan is a polysaccharide obtained from natural materials, and it has been reported that chitosan has excellent biocompatibility and biodegradability, cell association, biological tissue culture, and biological activities, such as antibacterial, aromatic, non-toxic, and hemostatic properties (Park Jun-gyu et al., 2015).
  • It is known that nucleic acids, which have been recognized as a genome to store and deliver genetic information, are distributed around the diseased tissue to promote cell growth and differentiation and angiogenesis and perform an inflammation inhibitory function. That is, nucleic acids are degraded into small fragments outside cells and bind to receptors on the cell surface to stimulate signals into the cells.
  • As for still another type of research, studies are being actively conducted in various fields, such as making very elaborate nanostructures using a self-assembly property inherent to nucleic acids. Since the formation results of hydrogels composed of DNA were reported in 2006 (Um S.H. et al., 2006), many groups have conducted studies about the formation of gels using DNA.
  • Hydrogels composed of DNA have very excellent biocompatibility, and thus are medically studied in various fields. The production results of functional DNA hydrogels that respond to heat and enzymes to induce free degradation and re-association have been recently reported (Xing Y. et al., 2011). Therefore, side effects due to overdosing of drugs can be reduced by enabling a smart drug delivery method in which drugs are allowed to flow only in case of necessity. Unlike existing hydrogel manufacturing methods using polymers, DNA hydrogels are composed of biomaterial DNA, and thus are not harmful to the human body, so the DNA hydrogels can be used as artificial tissues for wounded sites with various shapes and can be variously applied as an effective drug carrier in a medical field.
  • However, nucleic acids are easily degraded by degradation enzymes existing in the human body, so that the in vivo residence of nucleic acids for application of the nucleic acids to target disease tissues is low, resulting in a lack of drug persistence, and in the case where DNA hydrogels are utilized, the degradation of the nucleic acids by degradation enzymes causes a collapse of structures, and thus the DNA hydrogels may not properly perform as roles of artificial tissues and drug carriers (Lee Jong-beom, et al., 2012). Therefore, it is necessary to conduct research to enhance the drug persistence of nucleic acids and to solve the problems of DNA hydrogels.
  • The present inventors conducted continuous research in order to prepare a temperature-sensitive hydrogel, which exists in a sol state at room temperature and forms a gel when injected into the body, and as a result, the present inventors produced a temperature-sensitive hydrogel with biocompatibility and biodegradability through a combination of chitosan and a nucleic acid, and thus completed the present invention.
  • Korean Patent Publication No. 2014-0090670 as a prior art discloses an in-situ crosslinkable polymer composition, but never states temperature sensitivity and hydrogels. In addition, the crosslinkable polymer composition of this patent publication contains about 0.1 wt% to about 95 wt% of more than one kind of polyanionic polymer, about 0.1 wt% to about 90 wt% of more than one kind of polycationic polymer, and 0.1 wt% to 99.8 wt% of water, and thus this polymer composition is different from a temperature-sensitive hydrogel composition of the present invention in view of the mixing ratio. In addition, the patent publication discloses that the polyanions include crosslinkable and non-crosslinkable polyanions, and a polynucleotide is suggested as one of the non-crosslinkable polyanion components. However, the patent publication discloses that the non-crosslinkable polyanions are further included in the polyanions, and it can be seen that the non-crosslinkable anions do not influence crosslinkage. Whereas, a temperature-sensitive hydrogel of the present invention is formed through a non-crosslinkage between a nucleic acid and chitosan, and thus it can be seen that the temperature-sensitive hydrogel of the present invention is different from the polymer composition in the patent publication in view of the constituent elements. Furthermore, as a result of mixing 1 wt% of a nucleic acid and 0.1 wt% of chitosan with reference to the ratio supposed in Korean Patent Publication No. 2014-0090670 , it was confirmed that opaque white precipitates were generated and after 3 days, the layer separation occurred.
  • European Publication Patent No. 2745849 discloses a combination of polydeoxyribonucleotide (PDRN) and chitosan but does not state a temperature-sensitive hydrogel, wherein the combination contains 0.002-0.25 wt% of polydeoxyribonucleotide and 1-10 wt% of chitosan, which is different from the constitution of the present invention.
  • In addition, US Patent Publication No. 2015-0111834 discloses an in-situ gel composition, wherein an anti-gelation agent is introduced for prevention of gelation at room temperature, and thus it can be seen that the in-situ gel composition is different from the constitution of the present invention.
  • Detailed Description of the Invention Technical Problem
  • An aspect of the present invention is to provide a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan.
  • Technical Solution
  • In accordance with an aspect of the present invention, there is provided a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan, wherein the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1.
  • Preferably, the present invention may be a temperature-sensitive hydrogel composition wherein the weight ratio of a nucleic acid and chitosan is preferably 50:1 to 2000:1 and most preferably 100:1 to 1000:1.
  • The content of the nucleic acid may be 0.01 wt% to 3 wt% relative to the total weight of the composition.
  • The nucleic acid may be deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof.
  • The content of the chitosan may be 1x10-6 wt% to 0.15 wt% relative to the total weight of the composition.
  • The molecular weight of the chitosan may be 3 kDa to 1000 kDa.
  • Furthermore, the temperature-sensitive hydrogel composition may contain a polymer material as an additional ingredient.
  • The polymer material may be at least one selected from the group consisting of hyaluronic acid, poly-Y-glutamic acid, cellulose, polyacrylic acid, polyamino acids, alginate, and derivatives and a combination thereof.
  • In accordance with another aspect of the present invention, there is provided a method for producing the temperature-sensitive hydrogel composition, the method including: i) preparing a nucleic acid stock solution; ii) preparing a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of a nucleic acid and chitosan is 20:1 to 10000:1, followed by stirring; and iv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
  • The method may include: i) putting a nucleic acid in a buffer solution, and dissolving the nucleic acid in the buffer solution for 1-2 hours with stirring at 60-70Ā°C, to prepare a nucleic acid stock solution; ii) dissolving chitosan in an acidic buffer solution to prepare a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1, followed by stirring at 55-65Ā°C for 1-2 hours; and vi) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
  • The temperature-sensitive hydrogel composition may have an osmotic pressure of 100-500 mOsm and a pH value of 6-8.
  • Hereinafter, the present invention will be described in detail.
  • The temperature-sensitive hydrogel refers to a hydrogel of which a phase transition occurs from a sol into a gel or a gel into a sol according to the temperature. A transition of a sol into a gel is referred to as gelation. The gelation in the present invention is defined by a state in which a polymer having viscoelasticity forms a three-dimensional network structure with increasing temperature, and thus remains without being dissolved in a solvent.
  • In the temperature-sensitive hydrogel composition containing a nucleic acid and chitosan, the sol-gel transition temperature thereof may vary according to the mixing ratio of a nucleic acid and chitosan, and here, the sol-gel transition temperature can be adjusted by changing the mixing ratio according to the purpose for use.
  • The temperature-sensitive hydrogel composition containing a nucleic acid and chitosan is highly stable in which a homogeneous state is maintained and the layer separation does not occur. The weight ratio of the nucleic acid and the chitosan is in the range of preferably 20:1 to 10000:1, more preferably 50:1 to 2000:1, and most preferably 100:1 to 1000:1.
  • The content of the nucleic acid may be 0.01-3 wt%, preferably 0.1-2 wt%, and most preferably 1-1.5 wt% relative to the total weight of the composition.
  • The molecular weight of the nucleic acid may be 1-100,000 kDa, preferably 10-10,000 kDa, and most preferably 50-3,500 kDa.
  • The nucleic acid may be deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof. Preferably, the nucleic acid may be deoxyribonucleic acid.
  • In addition, the deoxyribonucleic acid may include oligonucleotides, polynucleotides, and polydeoxyribonucleotides (PDRN).
  • The nucleic acid may form a hydrogel through a combination with chitosan, and can act as a therapeutic drug in the body.
  • In addition, the content of chitosan may be 1x10-6 wt% to 0.15 wt%, preferably 1x10-5 wt% to 0.1 wt%, and most preferably 1x10-4 wt% to 0.075 wt%, relative to the total weight of the composition.
  • The molecular weight of chitosan is 3 kDa to 1000 kDa, but is not limited thereto.
  • In addition, the temperature-sensitive hydrogel composition may contain a polymer material as an additional ingredient, wherein the polymer material may be added to make secure the adjustment of physical property changes according to the use of the temperature-sensitive hydrogel containing the nucleic acid and chitosan.
  • The polymer material may employ at least one selected from the group consisting of hyaluronic acid, poly-Y-glutamic acid, cellulose, polyacrylic acid, polyamino acids, alginate, and derivatives and a combination thereof, but is not limited thereto.
  • In addition, the temperature-sensitive hydrogel composition may be used for a medical use and as a cosmetic agent.
  • A method for producing the temperature-sensitive hydrogel includes: i) putting a nucleic acid in a buffer solution, and dissolving the nucleic acid in the buffer solution for 1-2 hours with stirring at 60-70Ā°C, to prepare a nucleic acid stock solution; ii) dissolving chitosan in an acidic buffer solution to prepare a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1, followed by stirring at 55-65Ā°C for 1-2 hours; and iv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
  • The buffer solution that can be used in the preparation of the nucleic acid stock solution may employ sodium phosphate dibasic dodecahydrate, sodium chloride, magnesium chloride, potassium chloride, phosphate buffer saline, or HEPES (N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid) buffer solution, and preferably sodium phosphate dibasic dodecahydrate, but is not limited thereto.
  • The acidic buffer that can be used in the preparation of the chitosan stock solution may employ acetic acid, hydrochloric acid, ascorbic acid, lactic acid, and nitric acid, and preferably acetic acid, but is not limited thereto.
  • The mixing of the nucleic acid and the chitosan is conducted such that the weight ratio of nucleic acid and chitosan is 20:1 to 10000:1, and here, the content of the nucleic acid is 0.01-3 wt% relative to the total weight of the composition, and the content of the chitosan is 1x10-6 wt% to 0.15 wt% relative to the total weight of the composition.
  • As for the temperature-sensitive hydrogel composition obtained by the production method, the osmotic pressure and pH thereof may be adjusted so that the composition can be injected into the human body or coated on the skin.
  • For adjustment of pH of the temperature-sensitive hydrogel composition obtained by the production method, the production method may further include a step of adjusting pH in step iv).
  • The osmotic pressure of the temperature-sensitive hydrogel composition obtained by the production method may be 100-500 mOsm, preferably 150-450 mOsm, and most preferably 200-400 mOsm.
  • The pH of the temperature-sensitive hydrogel composition obtained by the production method may be 6-8, preferably 6.5-7.5, and most preferably 7.
  • Advantageous Effects
  • The present invention provides a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan. The hydrogel has excellent biocompatibility and biostability and exhibits a sol-gel transition property according to the temperature change, so that the hydrogel exists in a sol state at room temperature, and the hydrogel is gelated when the hydrogel has a high temperature by being injected into the body or coated on the epidermal skin surface.
  • Therefore, the temperature-sensitive hydrogel of the present invention can be directly injected and coated on a particular site in needed of therapy, and can increase the time for drug persistence and drug attachment through the gelation according to the temperature, and thus the drug efficacy thereof can sufficiently exerted. Therefore, the temperature-sensitive hydrogel is expected to be utilized in various therapies.
  • Brief Description of the Drawings
    • FIG. 1 shows the results of confirming physical property states of temperature-sensitive hydrogels according to the mixing ratio of a nucleic acid and chitosan. Each composition was subjected to mixing, and then was investigated for transparency and viscoelasticity (A) and precipitate generation and layer separation (B) for 3 days.
    • FIG. 2 shows the results of confirming whether gels are dissolved.
    • FIG. 3 shows the results of confirming the sol-gel transition of a temperature-sensitive hydrogel composition.
    Mode for Carrying Out the Invention
  • Hereinafter, preferable embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein but may be embodied in other forms. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
  • <Example 1: Production of nucleic acid-chitosan hydrogels>
  • For the production of nucleic acid and chitosan hydrogels, nucleic acid and chitosan stock solutions were prepared with concentrations corresponding examples shown in table 1 below. Here, nucleic acid was put in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate, and then dissolved therein using a heat stirrer at 65Ā°C for 1 hour.
  • In addition, chitosan was dissolved using 100 mM acetic acid.
  • The nucleic acid and chitosan stock solutions prepared with the concentrations in table 1 below were mixed at a weight ratio of 1:1, and stirred in a heat stirrer at 60Ā°C for 1 hour. Thereafter, the temperature was lowered to room temperature, followed by stirring for 1 hour, to produce nucleic acid-chitosan hydrogels.
  • <Comparative example 1: Production of comparative nucleic acid-chitosan hydrogel>
  • Nucleic acid and chitosan stock solutions were prepared with concentrations corresponding to comparative examples shown in table 1 below. Comparative nucleic acid-chitosan hydrogels were produced by the same method as in example 1. [Table 1]
    Constitution Stock solution concentration (wt%) Final concentration (wt%)
    Nucleic acid Chitosan Nucleic acid Chitosan
    Example 1-1 2 0.1 1 0.05
    Example 1-2 2 0.04 1 0.02
    Example 1-3 2 0.02 1 0.01
    Example 1-4 2 0.002 1 0.001
    Example 1-5 2 0.001 1 0.0005
    Example 1-6 2 0.0004 1 0.0002
    Example 1-7 2 0.0002 1 0.0001
    Example 1-8 0.02 0.0002 0.01 0.0001
    Example 1-9 0.02 0.00002 0.01 0.00001
    Example 1-10 6 0.06 3 0.03
    Example 1-11 6 0.006 3 0.003
    Comparative example 1-1 2 0 1 0
    Comparative example 1-2 0 0.02 0 0.01
    Comparative example 1-3 2 0.2 1 0.1
    Comparative example 1-4 2 0.0001 1 0.00005
  • <Example 2: Production of nucleic acid-chitosan-hyaluronic acid hydrogel>
  • A nucleic acid-chitosan-hyaluronic acid hydrogel was produced through the following procedure.
  • A nucleic acid was dissolved in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate to have a concentration of 2.2 wt%. Here, the nucleic acid were dissolved using a heat stirrer at 65Ā°C for 1 hour.
  • In addition, chitosan was dissolved in 100 mM acetic acid to have a concentration of 0.4 wt%.
  • Sodium hyaluronic acid was dissolved in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate to have a concentration of 2 wt%. Here, the sodium hyaluronic acid was dissolved using a heat stirrer at 40Ā°C for 30 minutes, followed by cooling to room temperature with stirring using a stirrer.
  • Then, 2.2 wt% of the prepared nucleic acid solution and 0.4 wt% of the prepared chitosan solution were mixed at a weight ratio of 9:1, followed by stirring in a heat stirrer at 65Ā°C for 10 minutes. 2 wt% of sodium hyaluronic acid was added to the nucleic acid-chitosan mixture solution at a weight ratio of 1:1, followed by stirring in a heat stirrer at 65Ā°C for 1 hour, and then the resulting solution was cooled to room temperature while the stirring maintained, thereby producing nucleic acid-chitosan-hyaluronic acid hydrogels of example 2.
  • <Comparative example 2: Production of comparative chitosan-hyaluronic acid hydrogel>
  • Chitosan and hyaluronic acid stock solutions were prepared with concentrations in table 2 below.
  • Chitosan was dissolved using 100 mM acetic acid.
  • Sodium hyaluronic acid was dissolved in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate. Here, sodium hyaluronic acid was dissolved using a heat stirrer at 40Ā°C for 30 minutes, and then the resulting solution was cooled to room temperature while the stirring was maintained. The prepared chitosan and hyaluronic acid solutions were mixed at a weight ratio of 1:1, followed by stirring in a heat stirrer at 65Ā°C for 1 hour. Thereafter, the temperature was lowered to room temperature, followed by stirring for 1 hour, to produce chitosan-hyaluronic acid hydrogels. [Table 2]
    Constitution Stock solution concentration (wt%) Final concentration (wt%)
    Chitosan Hyaluronic acid Chitosan Hyaluronic acid
    Comparative example 2-1 0 2 0 1
    Comparative example 2-2 0.02 2 0.01 1
  • <Experimental example 1: Confirmation of physical properties of nucleic acid-chitosan hydrogels>
  • The hydrogel compositions of example 1, example 2, comparative example 1, and comparative example 2 were used to investigate gelation, gel stability, and solubility thereof.
  • Each composition was subjected to mixing, and then the transparency and gelation state thereof were observed to the naked eye for 3 days. The gelation was examined by viscoelasticity and the gel stability was examined by precipitate generation and layer separation.
  • For the solubility of gel, the hydrogel composition of each of example 1, example 2, comparative example 1, and comparative example 2 was dropped in an aqueous solution at 37.5Ā°C, followed by gelation, and then the solubility of gel was examined while the stirring was conducted at 400 rpm for 5 minutes with the temperature maintained at 37.5Ā°C. The results were shown in table 3 and FIGS. 1 and 2. [Table 3]
    Constitution Results after three days Results of stirring at 37.5Ā°C for 5 minutes
    Viscoelasticity Precipitate generation Layer separation Gel solubility
    Example 1-1 ā—‹ Ɨ Ɨ Ɨ
    Example 1-2 ā—‹ Ɨ Ɨ Ɨ
    Example 1-3 ā—‹ Ɨ Ɨ Ɨ
    Example 1-4 ā—‹ Ɨ Ɨ Ɨ
    Example 1-5 ā—‹ Ɨ Ɨ Ɨ
    Example 1-6 ā—‹ Ɨ Ɨ Ɨ
    Example 1-7 ā—‹ Ɨ Ɨ Ɨ
    Example 1-8 ā—‹ Ɨ Ɨ Ɨ
    Example 1-9 ā—‹ Ɨ Ɨ Ɨ
    Example 1-10 ā—‹ Ɨ Ɨ Ɨ
    Example 1-11 ā—‹ Ɨ Ɨ Ɨ
    Example 2 ā—‹ Ɨ Ɨ Ɨ
    Comparative Example 1-1 ā—‹ Ɨ Ɨ ā—‹
    Comparative Example 1-2 Ɨ Ɨ Ɨ ā—‹
    Comparative Example 1-3 ā—‹ ā—‹ ā—‹ ā—‹
    Comparative Example 1-4 ā—‹ ā—‹ Ɨ ā—‹
    Comparative Example 2-1 Ɨ Ɨ Ɨ ā—‹
    Comparative Example 2-2 ā—‹ Ɨ Ɨ ā—‹
  • It can be seen from table 3 and FIG. 1 that, in the temperature-sensitive hydrogel compositions of examples 1-1 to 1-11, the precipitate isolation and the layer separation did not occur with viscoelasticity maintained, even three days after the nucleic acid and chitosan were mixed. However, as for comparative examples 1-1 to 1-4, which got out of the weight ratio range of nucleic acid and chitosan of the present invention, the precipitate generation, the layer separation, or the viscoelasticity was not observed.
  • In addition, it can be seen from the solubility of gel in table 3 and FIG. 2 that the temperature-sensitive hydrogel composition of each of examples 1-1 to 1-11 formed a gel at 37.5Ā°C and the formed gel was continuously maintained, whereas comparative examples 1-1 to 1-4 were not gelated at 37.5Ā°C or were completely dissolved within 20 seconds even if the gelation occurred.
  • It was confirmed that, even in example 2 in which hyaluronic acid as an additional ingredient was added in the nucleic acid and chitosan, the viscoelasticity was maintained even while the precipitate isolation and the layer separation were not shown and the gel was continuously maintained after the gelation, whereas in comparative example 2-2 in which the nucleic acid was not contained, the precipitate isolation and the layer separation were not shown with viscoelasticity maintained, but the gel was dissolved within 20 seconds after the gel was formed at 37.5Ā°C (see table 3 and FIG. 1).
  • Through these results, it can be seen that the hydrogel composition of the present invention shows temperature sensitivity, high stability, and a gel form continuously maintained after gelation, and here, it was confirmed that the weight ratio of nucleic acid and chitosan plays a key role.
  • <Experimental example 2: Confirmation of sol-gel transition with temperature>
  • The temperature-sensitive hydrogel composition produced in each of example 1, example 2, comparative example 1, and comparative example 2 was examined for sol-gel transition.
  • For the confirmation of sol-gel transition, a rheometer was used. The measurement conditions used here were PU20, gap of 0.5 mm, 0.1 Hz, and 1% stress-strain, and the changes of G' (elasticity) and G" (viscosity) were measured while the temperature was raised from 24Ā°C to 40Ā°C by 1Ā°C and then was maintained for 1 minute. In addition, the sol-gel transition after and before 36Ā°C was observed to the naked eye while the temperature of each composition was raised, and the results were shown in FIG. 3.
  • As shown in FIG. 3, it was observed that the temperature-sensitive hydrogel of example 1-3 exhibited a gentle decrease width of G' (elasticity) and an increase of G" (viscosity) with an increasing temperature (FIG. 3A), which correspond to the feature of a temperature-sensitive hydrogel. In addition, it was observed that the temperature-sensitive hydrogel of example 1-3 exhibited a sol state at a temperature lower than 36Ā°C but was gelated at a temperature exceeding 36Ā°C (FIG. 3B). It was confirmed that these results were identical in all of the temperature-sensitive hydrogel compositions in examples 1 and 2. It can be seen from these results that the hydrogel compositions of the present invention show temperature sensitivity.

Claims (13)

  1. A temperature-sensitive hydrogel composition containing a nucleic acid and chitosan, wherein the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1.
  2. The temperature-sensitive hydrogel composition of claim 1, wherein the weight ratio of the nucleic acid and the chitosan is 50:1 to 2000:1.
  3. The temperature-sensitive hydrogel composition of claim 2, wherein the weight ratio of the nucleic acid and the chitosan is 100:1 to 1000:1.
  4. The temperature-sensitive hydrogel composition of claim 1, wherein the content of the nucleic acid is 0.01 wt% to 3 wt% relative to the total weight of the composition.
  5. The temperature-sensitive hydrogel composition of claim 4, wherein the nucleic acid is deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof.
  6. The temperature-sensitive hydrogel composition of claim 1, wherein the content of the chitosan is 1x10-6 wt% to 0.15 wt% relative to the total weight of the composition.
  7. The temperature-sensitive hydrogel composition of claim 6, wherein the molecular weight of the chitosan is 3 kDa to 1,000 kDa.
  8. The temperature-sensitive hydrogel composition of claim 1, wherein the temperature-sensitive hydrogel composition contains a polymer material as an additional ingredient.
  9. The temperature-sensitive hydrogel composition of claim 8, wherein the polymer material is at least one selected from the group consisting of hyaluronic acid, poly-Y-glutamic acid, cellulose, polyacrylic acid, polyamino acids, alginate, and derivatives and a combination thereof.
  10. A method for producing the temperature-sensitive hydrogel composition of any one of claims 1 to 9, the method comprising:
    i) preparing a nucleic acid stock solution;
    ii) preparing a chitosan stock solution;
    iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of a nucleic acid and chitosan is 20:1 to 10000:1, followed by stirring; and
    iv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
  11. The method of claim 10, the method comprising:
    i) putting a nucleic acid in a buffer solution, and dissolving the nucleic acid in the buffer solution for 1-2 hours with stirring at 60-70Ā°C, to prepare a nucleic acid stock solution;
    ii) dissolving chitosan in an acidic buffer solution to prepare a chitosan stock solution;
    iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1, followed by stirring at 55-65Ā°C for 1-2 hours; and
    iv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
  12. The method of claim 10, wherein the temperature-sensitive hydrogel composition has an osmotic pressure of 100-500 mOsm.
  13. The method of claim 10, wherein the temperature-sensitive hydrogel composition has a pH value of 6-8.
EP16889476.4A 2016-02-05 2016-02-29 Temperature sensitive hydrogel composition including nucleic acid and chitosan Active EP3412313B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160015112A KR101666792B1 (en) 2016-02-05 2016-02-05 Thermosensitive hydrogel composition containing nucleic acid and chitosan
PCT/KR2016/002013 WO2017135498A1 (en) 2016-02-05 2016-02-29 Temperature sensitive hydrogel composition including nucleic acid and chitosan

Publications (3)

Publication Number Publication Date
EP3412313A1 true EP3412313A1 (en) 2018-12-12
EP3412313A4 EP3412313A4 (en) 2019-09-11
EP3412313B1 EP3412313B1 (en) 2020-08-26

Family

ID=57250289

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16889476.4A Active EP3412313B1 (en) 2016-02-05 2016-02-29 Temperature sensitive hydrogel composition including nucleic acid and chitosan

Country Status (6)

Country Link
US (1) US11672756B2 (en)
EP (1) EP3412313B1 (en)
JP (1) JP6533626B2 (en)
KR (1) KR101666792B1 (en)
CN (1) CN108697805B (en)
WO (1) WO2017135498A1 (en)

Families Citing this family (19)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
KR101666792B1 (en) 2016-02-05 2016-10-17 ģ£¼ģ‹ķšŒģ‚¬ ķŒŒė§ˆė¦¬ģ„œģ¹˜ķ”„ė”œė•ķŠø Thermosensitive hydrogel composition containing nucleic acid and chitosan
KR101916193B1 (en) * 2016-08-25 2018-11-07 ģ£¼ģ‹ķšŒģ‚¬ ķŒŒė§ˆė¦¬ģ„œģ¹˜ķ”„ė”œė•ķŠø Injectable composition comprising nucleic acid and chitosan for articular cavity
KR101959523B1 (en) * 2018-01-30 2019-03-18 ģ£¼ģ‹ķšŒģ‚¬ ķŒŒė§ˆė¦¬ģ„œģ¹˜ķ”„ė”œė•ķŠø Composition comprising nucleic acids, bone graft materials and cationic polymers for bone grafting and kit for manufacturing the same
JP7248956B2 (en) 2018-01-31 2023-03-30 äø‰č±ē“¦ę–Æ化学ę Ŗ式会ē¤¾ Composition, method for forming resist pattern, and method for forming insulating film
CN109265758B (en) * 2018-09-12 2020-12-04 南äŗ¬ęž—äøšå¤§å­¦ temperature/pH dual-response type chitin nanofiber hydrogel and preparation method thereof
CN109810265B (en) * 2018-12-28 2021-08-03 å¤©ę“„å¤§å­¦ DNA-polysaccharide hybrid hydrogel with volume change driven by solvent and preparation method thereof
KR102382257B1 (en) * 2019-03-21 2022-04-05 ģˆœģ²œķ–„ėŒ€ķ•™źµ ģ‚°ķ•™ķ˜‘ė „ė‹Ø Novel thermosensitive cellulose based hydrogel for post-surgical peritoneal adhesion prevention and preparation method thereof
EP3733755A1 (en) 2019-04-30 2020-11-04 Universita Degli Studi di Trieste Homogeneous hydrogels from chitosan oligosaccharide derivatives and applications thereof
KR102100506B1 (en) * 2019-06-27 2020-04-13 ģ£¼ģ‹ķšŒģ‚¬ ė©”ė””ķŒ¹ Thermosentitive chitosan hydrogel composition and bioinks composition comprising the same
KR102258224B1 (en) 2019-10-30 2021-05-31 ģƒėŖ…ėŒ€ķ•™źµ ģ²œģ•ˆģ‚°ķ•™ķ˜‘ė „ė‹Ø Electrolytic Device
KR102351107B1 (en) 2019-12-27 2022-01-14 ķ•œźµ­ź³¼ķ•™źø°ģˆ ģ—°źµ¬ģ› Hydrogel composition for pH control having antitumor effect and uses thereof
KR102547427B1 (en) 2020-01-22 2023-06-23 ģˆœģ²œķ–„ėŒ€ķ•™źµ ģ‚°ķ•™ķ˜‘ė „ė‹Ø Method for producing a temperature-sensitive cellulose-based hydrogel for preventing adhesion with mitomycin C release control function
CN111892689B (en) * 2020-08-14 2023-04-25 äøœå—å¤§å­¦ęˆč“¤å­¦é™¢ Nucleic acid hydrogel and preparation method thereof
CN114259460B (en) * 2020-09-16 2024-03-15 č‹å·žå¤§å­¦ Hydrogel composition based on immunoadjuvant and application thereof
CN113368037B (en) * 2021-06-15 2022-02-18 北äŗ¬å†œå­¦é™¢ Bovine lactoferrin peptide nanoparticle-loaded chitosan temperature-sensitive hydrogel and preparation method and application thereof
CN114058033B (en) * 2021-12-20 2024-06-04 ę²³å—ēœē§‘学院同位ē“ ē ”ē©¶ę‰€ęœ‰é™č“£ä»»å…¬åø Preparation method of temperature-sensitive hydrogel and temperature-sensitive hydrogel product prepared by same
CN114404358A (en) * 2022-01-21 2022-04-29 å‰ęž—å¤§å­¦ Preparation method of novel injectable drug-loaded hydrogel for treating osteosarcoma
PL443403A1 (en) 2023-01-03 2024-07-08 Politechnika Gdańska Hydrogel composite based on chitosan, method of producing a hydrogel composite based on chitosan and use of a composite in the form of bioink to create three-dimensional objects, especially using additive manufacturing technology, especially for the purpose of conducting cell cultures
CN116173292B (en) * 2023-04-19 2023-06-30 å‰ęž—å›åŒč”Œē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø Preparation method of antibacterial self-adhesion moisturizing nucleotide hydrogel dressing

Family Cites Families (13)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
EP1352072A4 (en) 2001-01-17 2004-09-01 Zycos Inc Nucleic acid delivery formulations
US8536230B2 (en) * 2006-01-25 2013-09-17 University Of Virginia Patent Foundation Methods for regulating gelation of polysaccharide solutions and uses thereof
EP2324045A4 (en) * 2008-08-05 2013-04-03 Univ Cornell Photo-crosslinked nucleic acid hydrogels
US8623403B2 (en) * 2009-12-02 2014-01-07 University Of Virginia Patent Foundation Methods for regulating gelation of hydrogel solutions and uses thereof
WO2012108606A1 (en) 2011-02-08 2012-08-16 ģ“ķ™”ģ—¬ģžėŒ€ķ•™źµ ģ‚°ķ•™ķ˜‘ė „ė‹Ø Sol-gel transition chitosan-polymer composite and use for same
EP2701753B1 (en) * 2011-04-27 2018-12-26 President and Fellows of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
MX366366B (en) 2011-11-13 2019-07-05 Cresilon Inc In-situ cross-linkable polymeric compositions and methods thereof.
ITTO20121107A1 (en) 2012-12-19 2014-06-20 Idea Medical Devices S R L COMPOSITION BASED ON POLYDESOSSYRIBONUCLEOTIDES AND RELATED USES
US9757330B2 (en) 2013-10-18 2017-09-12 Industrial Technology Research Institute Recipe for in-situ gel, and implant, drug delivery system formed thereby
CN103848928B (en) * 2014-01-28 2016-04-27 å—ę–¹åŒ»ē§‘å¤§å­¦å—ę–¹åŒ»é™¢ Injectable modified hyaluronic acid and preparation method thereof and composition
KR20150111834A (en) 2014-03-26 2015-10-06 ģ—˜ģ§€ģ „ģž ģ£¼ģ‹ķšŒģ‚¬ Mobile terminal and method for controlling the same
FR3029790B1 (en) 2014-12-12 2017-01-13 Synolyne Pharma CHITOSAN HYDROGEL MICROBELL
KR101666792B1 (en) 2016-02-05 2016-10-17 ģ£¼ģ‹ķšŒģ‚¬ ķŒŒė§ˆė¦¬ģ„œģ¹˜ķ”„ė”œė•ķŠø Thermosensitive hydrogel composition containing nucleic acid and chitosan

Also Published As

Publication number Publication date
WO2017135498A1 (en) 2017-08-10
CN108697805B (en) 2021-07-16
JP2019501928A (en) 2019-01-24
EP3412313A4 (en) 2019-09-11
EP3412313B1 (en) 2020-08-26
JP6533626B2 (en) 2019-06-19
US11672756B2 (en) 2023-06-13
CN108697805A (en) 2018-10-23
KR101666792B1 (en) 2016-10-17
US20190054015A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
EP3412313B1 (en) Temperature sensitive hydrogel composition including nucleic acid and chitosan
Peers et al. Chitosan hydrogels for sustained drug delivery
Dragan et al. Polysaccharides constructed hydrogels as vehicles for proteins and peptides. A review
Wu et al. Chitosan-based composite hydrogels for biomedical applications
AU2008296975B2 (en) Delayed self-gelling alginate systems and uses thereof
Wu et al. A thermo-and pH-sensitive hydrogel composed of quaternized chitosan/glycerophosphate
EP1753787B1 (en) Method of covalently linking hyaluronan and chitosan
ES2611105T3 (en) Three-dimensional nanocomposite materials consisting of a polysaccharide matrix and metal nanoparticles, preparation and use thereof
US20210015966A1 (en) Antibacterial Cellulose Hydrogels and Preparation Method therefor
Vasiliu et al. Chitosan-based polyelectrolyte complex hydrogels for biomedical applications
US20100279952A1 (en) Cross-linked hydrogel containing an active substance
Kong et al. The novel medical thermoresponsive hydrogel derived from chitosan
Siafaka et al. Polymer Based Gels: Recent and Future Applications in Drug Delivery Field
Feng et al. Natural hydrogels applied in photodynamic therapy
US20190184019A1 (en) Hydrogel and preparation method thereof
Lee et al. Preparation of collagen modified hyaluronan microparticles as antibiotics carrier
Neves et al. Plant polysaccharides in formulation coating
Giri et al. Polysaccharide Hydrogels for Drug Delivery and Regenerative Medicine
Debnath et al. Hydrogels based on chitosan
Antony et al. Introductory Aspects of Carboxymethyl Chitosan Derivatives
Nagpal et al. Pharmaceutical Applications of Gellan Gum
Sun et al. Thermosensitive injectable polysaccharide-based hydrogels: Gelation mechanisms, synthetic strategies, biomedical applications, and challenges
Nath et al. Ionotropic cross-linking methods for different types of biopolymeric hydrogels
Hamidi et al. An overview on current trends and future outlook of hydrogels in drug delivery.
Kumar et al. Use of Polysaccharides: Novel Delivery System for Genetic Material

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180801

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602016042991

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0047360000

Ipc: A61K0009080000

A4 Supplementary search report drawn up and despatched

Effective date: 20190813

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/08 20060101AFI20190807BHEP

Ipc: A61K 31/7088 20060101ALI20190807BHEP

Ipc: A61K 47/36 20060101ALI20190807BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200331

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016042991

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1305674

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201126

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201228

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201126

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201127

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200826

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1305674

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201226

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016042991

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20210527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20160229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240222

Year of fee payment: 9

Ref country code: GB

Payment date: 20240222

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240229

Year of fee payment: 9

Ref country code: FR

Payment date: 20240221

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200826